These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9376574)

  • 1. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients.
    Glaspy JA; Shpall EJ; LeMaistre CF; Briddell RA; Menchaca DM; Turner SA; Lill M; Chap L; Jones R; Wiers MD; Sheridan WP; McNiece IK
    Blood; 1997 Oct; 90(8):2939-51. PubMed ID: 9376574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
    Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
    Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients.
    Shpall EJ; Wheeler CA; Turner SA; Yanovich S; Brown RA; Pecora AL; Shea TC; Mangan KF; Williams SF; LeMaistre CF; Long GD; Jones R; Davis MW; Murphy-Filkins R; Parker WR; Glaspy JA
    Blood; 1999 Apr; 93(8):2491-501. PubMed ID: 10194427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
    Basser RL; To LB; Begley CG; Maher D; Juttner C; Cebon J; Mansfield R; Olver I; Duggan G; Szer J; Collins J; Schwartz B; Marty J; Menchaca D; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1998 May; 16(5):1899-908. PubMed ID: 9586908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.
    Weaver A; Chang J; Wrigley E; de Wynter E; Woll PJ; Lind M; Jenkins B; Gill C; Wilkinson PM; Pettengell R; Radford JA; Collins CD; Dexter TM; Testa NG; Crowther D
    J Clin Oncol; 1998 Aug; 16(8):2601-12. PubMed ID: 9704709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy.
    Prósper F; Solá C; Hornedo J; Arbona C; Menéndez P; Orfao A; Lluch A; Cortés-Funes H; López JJ; García-Conde J
    Leukemia; 2003 Feb; 17(2):437-41. PubMed ID: 12592344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.
    Grigg AP; Roberts AW; Raunow H; Houghton S; Layton JE; Boyd AW; McGrath KM; Maher D
    Blood; 1995 Dec; 86(12):4437-45. PubMed ID: 8541532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience.
    Anderlini P; Donato M; Chan KW; Huh YO; Gee AP; Lauppe MJ; Champlin RE; Körbling M
    Transfusion; 1999 Jun; 39(6):555-60. PubMed ID: 10378833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
    Gajewski JL; Rondon G; Donato ML; Anderlini P; Korbling M; Ippoliti C; Benyunes M; Miller LL; LaTemple D; Jones D; Ashby M; Hellmann S; Durett A; Lauppe J; Geisler D; Khouri IF; Giralt SA; Andersson B; Ueno NT; Champlin R
    Biol Blood Marrow Transplant; 2002; 8(10):550-6. PubMed ID: 12434950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.
    André M; Baudoux E; Bron D; Canon JL; D'Hondt V; Fassotte MF; D'Hondt L; Fillet G; Humblet Y; Jerusalem G; Vermeulen P; Symann M; Beguin Y
    Transfusion; 2003 Jan; 43(1):50-7. PubMed ID: 12519430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
    Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
    Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
    Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
    Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
    Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
    Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
    Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
    Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.
    Anderlini P; Donato M; Lauppe MJ; Huh YO; Martin TG; Chan KW; Champlin RE; Körbling M
    Br J Haematol; 2000 Jun; 109(4):770-2. PubMed ID: 10929027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.